Kisqali (ribociclib) vs Xeloda ()
Kisqali (ribociclib) vs Xeloda ()
Kisqali (ribociclib) is a targeted therapy known as a CDK4/6 inhibitor used primarily in combination with hormone therapy for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. Xeloda (capecitabine) is an oral chemotherapy drug that is metabolized into 5-fluorouracil (5-FU) in the body and is used to treat various types of cancer, including breast, colorectal, and gastric cancers. The choice between Kisqali and Xeloda would depend on the specific type of cancer, its molecular characteristics, the stage of the disease, and the patient's overall health status, as these medications have different mechanisms of action and are used in different clinical scenarios.
Difference between Kisqali and Xeloda
| Metric | Kisqali (ribociclib) | Xeloda (capecitabine) |
|---|---|---|
| Generic name | Ribociclib | Capecitabine |
| Indications | Advanced or metastatic breast cancer (HR-positive, HER2-negative) | Colorectal cancer, metastatic breast cancer |
| Mechanism of action | CDK4/6 inhibitor, halts cell cycle progression | Prodrug, converted to 5-fluorouracil, inhibits DNA synthesis |
| Brand names | Kisqali | Xeloda |
| Administrative route | Oral | Oral |
| Side effects | Neutropenia, nausea, infections, fatigue, diarrhea | Hand-foot syndrome, diarrhea, nausea, vomiting, fatigue |
| Contraindications | QT prolongation, liver disease, pregnancy | Dihydropyrimidine dehydrogenase (DPD) deficiency, severe renal impairment |
| Drug class | CDK4/6 inhibitor | Antimetabolite, fluoropyrimidine |
| Manufacturer | Novartis | Roche |
Efficacy
Kisqali (Ribociclib) Efficacy in Breast Cancer Treatment
Kisqali (ribociclib) is a targeted therapy drug used in the treatment of certain types of breast cancer. Specifically, it is approved for use in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. Ribociclib is a cyclin-dependent kinase inhibitor that works by interfering with the progression of the cell cycle, thereby inhibiting the proliferation of cancer cells.
Clinical trials have demonstrated the efficacy of Kisqali in improving progression-free survival in patients with advanced breast cancer. In the MONALEESA-2, MONALEESA-7, and MONALEESA-3 clinical trials, patients treated with ribociclib in combination with endocrine therapy had a significant delay in disease progression compared to those who received endocrine therapy alone. The MONALEESA trials showed that the addition of ribociclib resulted in a substantial increase in median progression-free survival, highlighting its benefit in the treatment regimen for eligible breast cancer patients.
Xeloda (Capecitabine) Efficacy in Breast Cancer Treatment
Xeloda (capecitabine) is an oral chemotherapy medication that is used to treat breast cancer among other types of cancer. It is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which is a cytotoxic agent that interferes with DNA synthesis and cell division. Xeloda is indicated for the treatment of patients with metastatic breast cancer, and it is often used when standard chemotherapy options have not been successful or in combination with other drugs for enhanced efficacy.
The efficacy of Xeloda in breast cancer treatment has been established through several clinical studies. In metastatic settings, Xeloda has been shown to be effective as a single agent and also in combination with other chemotherapeutic agents. Studies have indicated that Xeloda can improve response rates and may also contribute to an increase in overall survival in certain patient populations. Its oral administration is a significant advantage, providing a more convenient option for patients compared to intravenous chemotherapy regimens.
Regulatory Agency Approvals
Kisqali
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Xeloda
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Kisqali or Xeloda today
If Kisqali or Xeloda are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us